CN114848506A - 具有治疗特性的多功能个性化贴片 - Google Patents
具有治疗特性的多功能个性化贴片 Download PDFInfo
- Publication number
- CN114848506A CN114848506A CN202210561820.2A CN202210561820A CN114848506A CN 114848506 A CN114848506 A CN 114848506A CN 202210561820 A CN202210561820 A CN 202210561820A CN 114848506 A CN114848506 A CN 114848506A
- Authority
- CN
- China
- Prior art keywords
- patch
- layer
- skin
- colored
- modify
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001225 therapeutic effect Effects 0.000 title description 2
- 230000003287 optical effect Effects 0.000 claims abstract description 43
- 230000005540 biological transmission Effects 0.000 claims abstract description 19
- 239000000853 adhesive Substances 0.000 claims abstract description 17
- 230000001070 adhesive effect Effects 0.000 claims abstract description 17
- 230000031700 light absorption Effects 0.000 claims abstract description 17
- 239000010410 layer Substances 0.000 claims description 132
- 239000012790 adhesive layer Substances 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 230000008901 benefit Effects 0.000 claims description 13
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 9
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims 3
- 230000000873 masking effect Effects 0.000 abstract description 23
- 238000000034 method Methods 0.000 abstract description 22
- 238000010146 3D printing Methods 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 8
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 239000002537 cosmetic Substances 0.000 description 37
- 239000000463 material Substances 0.000 description 25
- 239000000049 pigment Substances 0.000 description 22
- 239000003086 colorant Substances 0.000 description 17
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 17
- 238000012986 modification Methods 0.000 description 17
- 230000004048 modification Effects 0.000 description 17
- -1 polydimethylsiloxane Polymers 0.000 description 17
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 239000000654 additive Substances 0.000 description 10
- 230000000996 additive effect Effects 0.000 description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 8
- 206010000496 acne Diseases 0.000 description 8
- 235000013980 iron oxide Nutrition 0.000 description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 208000002874 Acne Vulgaris Diseases 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 229920002529 medical grade silicone Polymers 0.000 description 6
- 239000000516 sunscreening agent Substances 0.000 description 6
- 239000004408 titanium dioxide Substances 0.000 description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 238000011960 computer-aided design Methods 0.000 description 5
- 238000007373 indentation Methods 0.000 description 5
- 239000003607 modifier Substances 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 5
- 239000004926 polymethyl methacrylate Substances 0.000 description 5
- 230000000475 sunscreen effect Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 229910010413 TiO 2 Inorganic materials 0.000 description 4
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 4
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 4
- 239000010445 mica Substances 0.000 description 4
- 229910052618 mica group Inorganic materials 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 238000002310 reflectometry Methods 0.000 description 4
- 229960003471 retinol Drugs 0.000 description 4
- 235000020944 retinol Nutrition 0.000 description 4
- 239000011607 retinol Substances 0.000 description 4
- 229960004889 salicylic acid Drugs 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000011787 zinc oxide Substances 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 239000004642 Polyimide Substances 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 239000003522 acrylic cement Substances 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 235000012730 carminic acid Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000000806 elastomer Substances 0.000 description 3
- 235000009569 green tea Nutrition 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000003605 opacifier Substances 0.000 description 3
- 229920001721 polyimide Polymers 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- VYGQUTWHTHXGQB-FFHKNEKCSA-N retinyl palmitate Natural products CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 3
- 229920002379 silicone rubber Polymers 0.000 description 3
- 239000004945 silicone rubber Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical class C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 240000007154 Coffea arabica Species 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 235000013628 Lantana involucrata Nutrition 0.000 description 2
- 240000005183 Lantana involucrata Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 235000010676 Ocimum basilicum Nutrition 0.000 description 2
- 240000007926 Ocimum gratissimum Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- 206010039580 Scar Diseases 0.000 description 2
- 235000010841 Silybum marianum Nutrition 0.000 description 2
- 206010040954 Skin wrinkling Diseases 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 229910021536 Zeolite Inorganic materials 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229950000210 beclometasone dipropionate Drugs 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 235000016213 coffee Nutrition 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013527 convolutional neural network Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 229960002887 deanol Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 2
- 229960002011 fludrocortisone Drugs 0.000 description 2
- 229940043075 fluocinolone Drugs 0.000 description 2
- 229960001347 fluocinolone acetonide Drugs 0.000 description 2
- 229960004881 homosalate Drugs 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- ROBFUDYVXSDBQM-UHFFFAOYSA-N hydroxymalonic acid Chemical compound OC(=O)C(O)C(O)=O ROBFUDYVXSDBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000001023 inorganic pigment Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001707 polybutylene terephthalate Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000306 polymethylpentene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229920000260 silastic Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 125000002640 tocopherol group Chemical class 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000010457 zeolite Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RDEIXVOBVLKYNT-HDZPSJEVSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-[(1r)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2 Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)[C@@H](C)N)N)[C@@H](N)C[C@H]1N.O1[C@H]([C@@H](C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-HDZPSJEVSA-N 0.000 description 1
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- 150000000183 1,3-benzoxazoles Chemical class 0.000 description 1
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- OSNILPMOSNGHLC-UHFFFAOYSA-N 1-[4-methoxy-3-(piperidin-1-ylmethyl)phenyl]ethanone Chemical compound COC1=CC=C(C(C)=O)C=C1CN1CCCCC1 OSNILPMOSNGHLC-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 description 1
- HUADITLKOCMHSB-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2s,4r)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 HUADITLKOCMHSB-AVQIMAJZSA-N 0.000 description 1
- OGQYJDHTHFAPRN-UHFFFAOYSA-N 2-fluoro-6-(trifluoromethyl)benzonitrile Chemical compound FC1=CC=CC(C(F)(F)F)=C1C#N OGQYJDHTHFAPRN-UHFFFAOYSA-N 0.000 description 1
- 229940099451 3-iodo-2-propynylbutylcarbamate Drugs 0.000 description 1
- WYVVKGNFXHOCQV-UHFFFAOYSA-N 3-iodoprop-2-yn-1-yl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 description 1
- VOXXWSYKYCBWHO-UHFFFAOYSA-N 3-phenyllactic acid Chemical compound OC(=O)C(O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-UHFFFAOYSA-N 0.000 description 1
- VOBDXTSTTMAKHK-VHDCPBDGSA-N 3870-07-3 Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O VOBDXTSTTMAKHK-VHDCPBDGSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-M 4-aminobenzoate Chemical compound NC1=CC=C(C([O-])=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-M 0.000 description 1
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 244000303769 Amaranthus cruentus Species 0.000 description 1
- 235000015363 Amaranthus cruentus Nutrition 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 235000015700 Artemisia abrotanum Nutrition 0.000 description 1
- 244000249062 Artemisia abrotanum Species 0.000 description 1
- 235000003092 Artemisia dracunculus Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- 208000003643 Callosities Diseases 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 241000209205 Coix Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- HHJIUUAMYGBVSD-YTFFSALGSA-N Diflucortolone valerate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)CCCC)[C@@]2(C)C[C@@H]1O HHJIUUAMYGBVSD-YTFFSALGSA-N 0.000 description 1
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 1
- 239000004716 Ethylene/acrylic acid copolymer Substances 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 240000005074 Hymenocallis caribaea Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 235000003368 Ilex paraguariensis Nutrition 0.000 description 1
- 244000188472 Ilex paraguariensis Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 241001648859 Lilium candidum Species 0.000 description 1
- 241001071917 Lithospermum Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 235000005135 Micromeria juliana Nutrition 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 229920000299 Nylon 12 Polymers 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 241001529744 Origanum Species 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 239000007977 PBT buffer Substances 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- AVFIYMSJDDGDBQ-UHFFFAOYSA-N Parthenium Chemical compound C1C=C(CCC(C)=O)C(C)CC2OC(=O)C(=C)C21 AVFIYMSJDDGDBQ-UHFFFAOYSA-N 0.000 description 1
- 241001495454 Parthenium Species 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004697 Polyetherimide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 241001083505 Punica Species 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 235000017848 Rubus fruticosus Nutrition 0.000 description 1
- 235000007315 Satureja hortensis Nutrition 0.000 description 1
- 240000002114 Satureja hortensis Species 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 244000272459 Silybum marianum Species 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 240000004460 Tanacetum coccineum Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 244000078534 Vaccinium myrtillus Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- VLHRIOASVODQEX-WLDNQIQOSA-N [2-[(6s,8s,9s,10r,11s,13s,14s,16r,17s)-6-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(C)=O)[C@@]2(C)C[C@@H]1O VLHRIOASVODQEX-WLDNQIQOSA-N 0.000 description 1
- ULGYAEQHFNJYML-UHFFFAOYSA-N [AlH3].[Ca] Chemical compound [AlH3].[Ca] ULGYAEQHFNJYML-UHFFFAOYSA-N 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000010476 amaranth oil Substances 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229960003204 amorolfine Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- ILZWGESBVHGTRX-UHFFFAOYSA-O azanium;iron(2+);iron(3+);hexacyanide Chemical compound [NH4+].[Fe+2].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] ILZWGESBVHGTRX-UHFFFAOYSA-O 0.000 description 1
- UHHXUPJJDHEMGX-UHFFFAOYSA-K azanium;manganese(3+);phosphonato phosphate Chemical compound [NH4+].[Mn+3].[O-]P([O-])(=O)OP([O-])([O-])=O UHHXUPJJDHEMGX-UHFFFAOYSA-K 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- MGFRKBRDZIMZGO-UHFFFAOYSA-N barium cadmium Chemical compound [Cd].[Ba] MGFRKBRDZIMZGO-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 229940024874 benzophenone Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960001102 betamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 229960002962 butenafine Drugs 0.000 description 1
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- CNYFJCCVJNARLE-UHFFFAOYSA-L calcium;2-sulfanylacetic acid;2-sulfidoacetate Chemical compound [Ca+2].[O-]C(=O)CS.[O-]C(=O)CS CNYFJCCVJNARLE-UHFFFAOYSA-L 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- DGQLVPJVXFOQEV-NGOCYOHBSA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-NGOCYOHBSA-N 0.000 description 1
- 229940114118 carminic acid Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- ZLFVRXUOSPRRKQ-UHFFFAOYSA-N chembl2138372 Chemical compound [O-][N+](=O)C1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 ZLFVRXUOSPRRKQ-UHFFFAOYSA-N 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229950006229 chloroprednisone Drugs 0.000 description 1
- NPSLCOWKFFNQKK-ZPSUVKRCSA-N chloroprednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](Cl)C2=C1 NPSLCOWKFFNQKK-ZPSUVKRCSA-N 0.000 description 1
- 229960003185 chlortetracycline hydrochloride Drugs 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- 229960004375 ciclopirox olamine Drugs 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229940017545 cinnamon bark Drugs 0.000 description 1
- CMDKPGRTAQVGFQ-RMKNXTFCSA-N cinoxate Chemical compound CCOCCOC(=O)\C=C\C1=CC=C(OC)C=C1 CMDKPGRTAQVGFQ-RMKNXTFCSA-N 0.000 description 1
- 229960001063 cinoxate Drugs 0.000 description 1
- 229960002291 clindamycin phosphate Drugs 0.000 description 1
- 229960005228 clioquinol Drugs 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- FCSHDIVRCWTZOX-DVTGEIKXSA-N clobetasol Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O FCSHDIVRCWTZOX-DVTGEIKXSA-N 0.000 description 1
- 229960001146 clobetasone Drugs 0.000 description 1
- XXIFVOHLGBURIG-OZCCCYNHSA-N clobetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)CC2=O XXIFVOHLGBURIG-OZCCCYNHSA-N 0.000 description 1
- 229960004299 clocortolone Drugs 0.000 description 1
- YMTMADLUXIRMGX-RFPWEZLHSA-N clocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O YMTMADLUXIRMGX-RFPWEZLHSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- XCJYREBRNVKWGJ-UHFFFAOYSA-N copper(II) phthalocyanine Chemical compound [Cu+2].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 XCJYREBRNVKWGJ-UHFFFAOYSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960004833 dexamethasone phosphate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960002124 diflorasone diacetate Drugs 0.000 description 1
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
- 229960003970 diflucortolone valerate Drugs 0.000 description 1
- 229960004875 difluprednate Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- VEVFSWCSRVJBSM-HOFKKMOUSA-N ethyl 4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 VEVFSWCSRVJBSM-HOFKKMOUSA-N 0.000 description 1
- UHESRSKEBRADOO-UHFFFAOYSA-N ethyl carbamate;prop-2-enoic acid Chemical compound OC(=O)C=C.CCOC(N)=O UHESRSKEBRADOO-UHFFFAOYSA-N 0.000 description 1
- 229940117360 ethyl pyruvate Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 229960004207 fentanyl citrate Drugs 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229960002650 fluprednidene acetate Drugs 0.000 description 1
- DEFOZIFYUBUHHU-IYQKUMFPSA-N fluprednidene acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC(=C)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O DEFOZIFYUBUHHU-IYQKUMFPSA-N 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 239000001056 green pigment Substances 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 229960001906 haloprogin Drugs 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229960003258 hexylresorcinol Drugs 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 229940049673 ilex paraguariensis leaf extract Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- BTNMPGBKDVTSJY-UHFFFAOYSA-N keto-phenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=CC=C1 BTNMPGBKDVTSJY-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- CWKLZLBVOJRSOM-UHFFFAOYSA-N methyl pyruvate Chemical compound COC(=O)C(C)=O CWKLZLBVOJRSOM-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229940096421 milk thistle extract Drugs 0.000 description 1
- 235000020727 milk thistle extract Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- IYIYMCASGKQOCZ-DJRRULDNSA-N motretinide Chemical compound CCNC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C IYIYMCASGKQOCZ-DJRRULDNSA-N 0.000 description 1
- 229960005406 motretinide Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 235000019508 mustard seed Nutrition 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- PYUYQYBDJFMFTH-WMMMYUQOSA-N naphthol red Chemical compound CCOC1=CC=CC=C1NC(=O)C(C1=O)=CC2=CC=CC=C2\C1=N\NC1=CC=C(C(N)=O)C=C1 PYUYQYBDJFMFTH-WMMMYUQOSA-N 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229940114496 olive leaf extract Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 239000001053 orange pigment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 229920009441 perflouroethylene propylene Polymers 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 235000010204 pine bark Nutrition 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002577 polybenzoxazole Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- HYTYHTSMCRDHIM-UHFFFAOYSA-M potassium;2-sulfanylacetate Chemical compound [K+].[O-]C(=O)CS HYTYHTSMCRDHIM-UHFFFAOYSA-M 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- WUBJISGMPZWFKY-UHFFFAOYSA-N propan-2-yl 2-oxopropanoate Chemical compound CC(C)OC(=O)C(C)=O WUBJISGMPZWFKY-UHFFFAOYSA-N 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 229950005137 saperconazole Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 229960005429 sertaconazole Drugs 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000037370 skin discoloration Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 230000037339 smooth wrinkles Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- VVNRQZDDMYBBJY-UHFFFAOYSA-M sodium 1-[(1-sulfonaphthalen-2-yl)diazenyl]naphthalen-2-olate Chemical compound [Na+].C1=CC=CC2=C(S([O-])(=O)=O)C(N=NC3=C4C=CC=CC4=CC=C3O)=CC=C21 VVNRQZDDMYBBJY-UHFFFAOYSA-M 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- KKVTYAVXTDIPAP-UHFFFAOYSA-M sodium;methanesulfonate Chemical compound [Na+].CS([O-])(=O)=O KKVTYAVXTDIPAP-UHFFFAOYSA-M 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 150000003669 ubiquinones Chemical class 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- 229910001845 yogo sapphire Inorganic materials 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 150000003772 α-tocopherols Chemical class 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 150000003781 β-tocopherols Chemical class 0.000 description 1
- 150000003785 γ-tocopherols Chemical class 0.000 description 1
- 150000003789 δ-tocopherols Chemical class 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00059—Accessories for dressings provided with visual effects, e.g. printed or colored
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0226—Adhesive bandages or dressings with fluid retention members characterised by the support layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
- A61F13/0289—Apparatus or processes for manufacturing adhesive dressings or bandages manufacturing of adhesive dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00153—Wound bandages coloured or with decoration pattern or printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/0037—Plasters use for cosmesis
- A61F2013/00378—Plasters use for cosmesis coloured as the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00846—Plasters with transparent or translucent part
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/0091—Plasters containing means with disinfecting or anaesthetics means, e.g. anti-mycrobic
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Manufacturing & Machinery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Laminated Bodies (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明提供了具有掩饰和/或有益特性的细心搭配贴片,其可形成以用于向期望的人类皮肤区域施用。该贴片包含柔性膜,所述柔性膜具有第一面向外的粘合剂主表面和第二面向外的表面,所述第二面向外的表面经纹理化以对应于使用期间被所述贴片覆盖的皮肤;其中所述柔性膜还包括至少一个着色区域和至少一个适于改性一个或多个光学特性的区域,所述一个或多个光学特性选自光透射、光反射和光吸收。本发明还提供了此类贴片的定制使用方法,该方法可包括3D打印工艺。
Description
技术领域
本发明涉及一种掩饰化妆贴片,其用于向个体皮肤施用以遮盖或遮藏不期望的皮肤特性。具体地,本发明为一种用于向个体皮肤施用的粘合剂贴片以及一种使用此类贴片的方法,该粘合剂贴片模拟下面皮肤的外观。
背景技术
掩饰化妆品是掩盖皮肤缺陷(诸如痤疮疤痕)以及皮肤变色(诸如皮肤上的白斑、使皮肤发红的皮炎和手术疤痕)的领域。它也被称为医疗化妆品、矫正型掩饰化妆品或掩饰化妆品。它通常以霜膏和/或粉末的形式存在,以遮藏面部或身体的颜色或轮廓的不规整或异常。
最近,已报道以单个层覆盖这些缺陷的贴片,诸如临时纹身或垫片,其中垫片的顶部表面涂有颜色匹配颜料。
然而,这些方法不复制皮肤的天然皮肤颜色和光学特性,并且不处理不想要的皮肤状况。
需要各种类型的掩饰化妆品,它们提供针对不想要的皮肤状况的优越皮肤掩饰能力,从而提供优异的皮肤颜色匹配并且匹配消费者天然皮肤的光学特性,同时递送制剂和/或活性物质以处理不想要的皮肤状况。
发明内容
令人惊讶的是,我们已发现具有掩饰和/或有益特性的细心搭配贴片可形成以用于向期望的人类皮肤区域施用。在一个实施方案中,该贴片包含柔性膜,所述柔性膜具有第一面向外的粘合剂主表面和第二面向外的表面,所述第二面向外的表面经纹理化以对应于使用期间被所述贴片覆盖的皮肤;其中所述柔性膜还包括至少一个着色区域和至少一个适于改性一个或多个光学特性的区域,所述一个或多个光学特性选自光透射、光反射和光吸收。
在另一个实施方案中,该贴片包含第一面向外的粘合剂主表面;第二面向外的表面,所述第二面向外的表面经纹理化以对应于使用期间被所述贴片覆盖的皮肤;至少一个着色层;以及至少一个适于改性一个或多个光学特性的层,所述一个或多个光学特性选自光透射、光反射和光吸收。
在另一个实施方案中,该贴片包含柔性膜,所述柔性膜具有第一面向外的粘合剂层、与所述第一面向外的粘合剂层相对的第二面向外的主表面,所述第二面向外的主表面经纹理化以对应于使用期间被所述贴片覆盖的皮肤;其中所述柔性膜还包括设置在所述第一面向外的粘合剂层和所述第二面向外的主表面之间的至少一个着色层和至少一个适于改性一个或多个光学特性的层,所述一个或多个光学特性选自光透射、光反射和光吸收。
在第四实施方案中,该贴片包含多个层,具有粘合剂的第一外层,第一外表面,第二外表面,与粘合剂层相关联的第一层;具有与其相关联的至少一个形成纹理化表面的层的第二外层,以及至少一个设置在所述第一粘合剂层和所述第二外表面之间的中间层,所述至少一个中间层具有至少一个着色区域或层以及至少一个适于改性一个或多个光学特性的区域或层,所述一个或多个光学特性选自光透射、光反射和光吸收。
本发明的第五实施方案涉及一种在期望的人类皮肤区域中掩饰瑕疵的方法。该方法包括以下步骤:(a)将与所述期望的人类皮肤区域相关的图像数据提供给计算机,其中所述计算机将所述图像数据转换成几何数据,所述几何数据代表所述期望的人类皮肤区域的几何模型;(b)使用所述几何数据来控制3D打印机以打印连续的柔性材料层以形成用于向所述期望的人类皮肤区域施用的贴片,所述贴片包含柔性膜,所述柔性膜具有第一面向外的粘合剂主表面和第二面向外的表面,所述第二面向外的表面经纹理化以对应于使用期间被所述贴片覆盖的皮肤;其中所述柔性膜还包括至少一个着色区域和至少一个适于改性一个或多个光学特性的区域,所述一个或多个光学特性选自光透射、光反射和光吸收;以及(c)向所述期望的人类皮肤区域施用所述贴片。
附图说明
图1为本发明的掩饰化妆贴片的第一实施方案的透视图;
图2为图1的掩饰化妆贴片实施方案的顶视图;
图3为图1的掩饰化妆贴片实施方案在x—z平面中的剖视图;
图4为本发明的掩饰化妆贴片的第二实施方案的透视图;
图5为图4的掩饰化妆贴片实施方案在x—z平面中的剖视图;
图6为本发明的掩饰化妆贴片的第三实施方案在x—z平面中的剖视图;并且
图7为本发明的掩饰化妆贴片的第四实施方案在x—z平面中的剖视图。
具体实施方式
本发明涉及一种掩饰化妆贴片,其提供针对不想要的皮肤状况(诸如粉刺、疤痕、湿疹和牛皮癣)的优越皮肤掩饰能力。给出以下描述以使得本领域的普通技术人员能够制备并使用本发明。对本文描述的实施方案和一般性原理以及特征的各种修正对本领域的技术人员来说将显而易见。因此,本发明并非旨在限于所示出的实施方案,而是被赋予符合本文所描述的原理和特征的最广范围。
如在本文的说明书和权利要求书中所用,术语“局部”及其变型意指身体的孤立部分或施用到身体的孤立部分。这包括但不限于皮肤、粘膜和釉质。
如本文所用,“有益剂”意指提供有益效果,例如在美容方面或在治疗方面改善、减轻、减少或治疗皮肤的症状或状况的成分或材料。
本文所述的用于处理常见消费者皮肤缺陷的方法使用个性化掩饰贴片,该个性化掩饰贴片提供优异的皮肤颜色匹配并且保持消费者天然皮肤的光学特性。在一些实施方案中,它还可递送制剂和/或活性物质以处理不想要的皮肤状况。该贴片具有多层制造构造,所述多层制造构造提供最佳的皮肤颜色、透明度、纹理和不透明品质以完美匹配消费者的天然皮肤。该多层构造提供匹配消费者皮肤颜色的皮肤纹理层、用于模拟天然皮肤光学特性的多个光吸收和反射层、以及用于制剂和活性物质递送以处理皮肤并且用作粘合剂层以将贴片保持在适当位置的一个或多个层。
图1至图3示出了本发明的掩饰化妆贴片10的第一实施方案。图1为贴片10的透视图,其包含柔性膜20,该柔性膜具有第一面向外的主表面22和第二面向外的主表面24。第一面向外的主表面22粘附到使用者的皮肤。第二面向外的主表面24具有基本上对应于遮藏皮肤的表面纹理元件26。贴片10的厚度介于约0.01mm和约1mm之间。
图2为掩饰化妆贴片10的顶视图。该图示出了第二面向外的主表面24上的表面纹理元件26。图3为掩饰化妆贴片10在x—z平面中的剖视图。该图示出了柔性膜20,该柔性膜具有着色区域30,以及被称为光学改性区域40的包含光学改性材料的区域。
第一面向外的主表面22粘附到使用者的皮肤。如本文所用,“粘合剂”是指致使某种物质(在这种情况下)粘附到使用者皮肤的材料或物质。在一些实施方案中,面向外的主表面22包含压敏粘合剂层。
图1至图3示出具有表面纹理元件26的第二面向外的主表面24。如本文所用,“纹理”是指主表面24的表面品质由表面的粗糙度或光滑度来测量。在该实施方案中,主表面24上的表面纹理元件26被示出为表面24上连续的凹痕线。应当理解,表面纹理元件26也可包括但不限于不连续的凹痕线、凹痕区域,以及连续或不连续的表面凸起线、表面凸起区域,以及具有凹痕和凸起的表面。
柔性膜20具有着色区域30。着色区域30包含用于在贴片10施用区域中匹配使用者皮肤颜色的颜料。着色区域30通过将着色剂混合到相对中性或无色材料的基质中而形成。下文将讨论关于着色剂和基质材料的细节。
另外,柔性膜20具有光学改性区域40。这些区域中的材料可改性以下光学特性中的一个或多个:光透射、光反射和光吸收。图3示出具有多个横截面几何形状的光学改性区域40。这些横截面几何形状包括椭圆形(40a)、三角形(40b)、正方形(40c)、矩形(40d和40e)、以及梯形(40f)。在一些实施方案中,光学改性区域诸如区域40b和40c从第一面向外的主表面22跨到第二面向外的主表面24。在一些实施方案中,光学改性区域诸如区域40d和40e跨越堆叠在第一面向外的主表面22和第二面向外的主表面24之间。
光学改性区域40通过将光学改性剂混合到相对中性或无色材料的基质中而形成。下文将讨论关于光学改性剂和基质材料的细节。
在图3中以连续方式示出了着色区域30,其中区域40为离散的。在一些实施方案中,着色区域30可为离散的,其中区域40为连续的。在其他实施方案中,柔性膜20可具有连续和离散的着色区域30,以及连续和离散的光学改性区域40。
在使用中,构成贴片10的柔性膜20被布置和构造成覆盖皮肤瑕疵。此处,着色区域30和至少一个光学改性区域40(适于改性一个或多个光学特性的区域)被布置和构造成对应于无瑕疵皮肤。
图4和图5示出了本发明的掩饰化妆贴片100的第二实施方案。图4为贴片100的透视图,而图5为掩饰化妆贴片100在x—z平面中的剖视图。这些图示出了贴片100,该贴片具有柔性膜120,该柔性膜具有第一面向外的主表面122和第二面向外的主表面124。第一面向外的主表面122粘附到使用者的皮肤。在一些实施方案中,面向外的主表面122包含压敏粘合剂层。第二面向外的主表面124具有基本上对应于遮藏皮肤的表面纹理元件126。这些图还示出了柔性膜120,该柔性膜具有着色层130,以及被称为光学改性层140的包含光学改性材料的层。
第二面向外的主表面124具有表面纹理元件126,其被示出为表面124上连续的凹痕线。
柔性膜120具有包含用于在贴片100的区域中匹配使用者皮肤颜色的颜料的着色层130以及光学改性层140。层140中的材料可改性以下光学特性中的一个或多个:光透射、光反射和光吸收。
图4和图5示出了掩饰化妆贴片100的实施方案,其具有单个着色层130以及单个光学改性层140。在其它实施方案中,贴片100可具有多个着色层130和/或光学改性层140。这些图还示出了在本发明的实施方案中,着色层130相邻于第二面向外的主表面124,而光学改性层140相邻于第一面向外的主表面122。在其它实施方案中,贴片100可具有相邻于第一面向外的主表面122的着色层130,而光学改性层140相邻于第二面向外的主表面124。在存在多个着色层130和/或光学改性层140的其他实施方案中,可存在着色层130或光学改性层140,它们相邻于第一面向外的主表面122或第二面向外的主表面124。
在一些实施方案中,着色层130是连续地着色的,而在其他实施方案中,着色层130具有由非着色区域隔开的离散着色区域。在其它实施方案中,着色层130具有至少一个第一着色区域和至少一个第二着色区域,其中所述第一着色区域和所述第二着色区域是不同地着色的。
在使用中,构成贴片100的柔性膜120被布置和构造成覆盖皮肤瑕疵。此处,着色层130和至少一个光学改性层140(适于改性一个或多个光学特性的区域)被布置和构造成对应于无瑕疵皮肤。
图6为本发明的掩饰化妆贴片200的第三实施方案在x—z平面中的剖视图。该图示出了贴片200,该贴片具有柔性膜220,该柔性膜具有第一面向外的主表面222和第二面向外的主表面224。第一面向外的主表面222具有粘合剂层250,以便粘附到使用者的皮肤。粘合剂层250可为连续的粘合剂层,或者可具有离散的粘合剂区域。在一些实施方案中,粘合剂层250可为压敏粘合剂。第二面向外的主表面224具有基本上对应于遮藏皮肤的表面纹理元件226。该图还示出了柔性膜220,该柔性膜具有着色层230,以及被称为光学改性层240的包含光学改性材料的层。
第二面向外的主表面224上的表面纹理元件226被示出为表面224上连续的凹痕线,但如先前所讨论,它们可为不连续的凹痕线、凹痕区域,以及连续或不连续的表面凸起线、表面凸起区域,以及具有凹痕和凸起的表面。
柔性膜220具有包含用于在掩饰化妆贴片200的区域中匹配使用者皮肤颜色的颜料的着色层230以及光学改性层240。层240中的材料可改性以下特性中的一个或多个:光透射、光反射和光吸收。
还如早先所讨论,掩饰化妆贴片200的第三实施方案具有单个着色层230以及单个光学改性层240。在其它实施方案中,贴片200可具有多个着色层230和/或光学改性层240。另外,着色层230被示为相邻于第二面向外的主表面224,并且光学改性层240相邻于第一面向外的主表面222。在其它实施方案中,着色层230可相邻于第一面向外的主表面222,而光学改性层240可相邻于第二面向外的主表面224。在具有多个着色层230和/或光学改性层240的其他实施方案中,可存在着色层230和/或光学改性层240,它们相邻于第一面向外的主表面222或第二面向外的主表面224。
在使用中,构成贴片200的柔性膜220被布置和构造成覆盖皮肤瑕疵。此处,着色层230和至少一个光学改性层240(适于改性一个或多个光学特性的区域)被布置和构造成对应于无瑕疵皮肤。
图7为本发明的掩饰化妆贴片300的第四实施方案在x—z平面中的剖视图。该图示出了贴片300,该贴片具有柔性膜320,该柔性膜具有第一面向外的主表面322和第二面向外的主表面324。第一面向外的主表面322具有非连续的粘合剂层370,以便粘附到使用者的皮肤。尽管被示出为非连续的,但粘合剂层370可为连续的粘合剂层,或者可具有离散的粘合剂区域。在一些实施方案中,粘合剂层370可为压敏粘合剂。第二面向外的主表面324具有基本上对应于遮藏皮肤的表面纹理元件326。该图还示出了柔性膜320,该柔性膜具有着色层330,以及光学地改性光透射、光反射或光吸收的层。光学地改性的层被称为透射改性层340、反射改性层350和吸收改性层360。
第二面向外的主表面324上的表面纹理元件326被示出为表面324上连续的凹痕线,并且着色层330包含用于在掩饰化妆贴片300的区域中匹配使用者皮肤颜色的颜料。
图7示出了掩饰化妆贴片300,其具有单个着色层330以及单个透射改性层340、反射改性层350和吸收改性层360。在其它实施方案中,贴片300可具有多个着色层330和/或光学改性层(340、350、360)。另外,图7将从第二面向外的主表面324到第一面向外的主表面322的层顺序示出为:着色层330、透射改性层340、反射改性层350和吸收改性层360。在其他实施方案中,层顺序可不同,这取决于掩饰化妆贴片300使用者的需要。
基质材料
存在多种基质材料,它们可用于着色区域/层(30、130、230和330)以及改性区域(40、140、240、340、350和350)。材料列表包括但不限于明胶、琼脂、有机硅诸如MDX4-4210(Dow Corning Corp.)、A型硅橡胶医疗有机硅粘合剂(Dow Corning Corp.)、聚甲基硅氧烷、聚二甲基硅氧烷、硅烷、聚酯(诸如PET)、聚丙烯酸酯(诸如PMMA)、聚碳酸酯、聚丙烯、高密度和低密度聚乙烯、聚亚烯萘、聚砜、聚醚砜、聚氨酯、聚酰胺、乙酸丁酸纤维素、聚乙烯醇缩丁醛、聚氯乙烯、聚偏二氟乙烯(PVDF)、氟化乙烯丙烯(PEF)、聚氟乙烯、聚醚酰亚胺、PETG、ABS、SIS、聚酰亚胺、环氧树脂、PBT、PVDF、聚丁-1-烯、聚(4-甲基戊烯-1)、马来酰亚胺-异丁烯共聚物、羟基聚(醚砜)、氨酯丙烯酸酯、丙烯类有机硅、有机硅-氨酯共聚物、EVA、己内酯、PLA、PGLA、EM/AGM共聚物(乙烯-丙烯酸甲酯-甲基丙烯酸缩水甘油酯)、纤维素衍生物、聚酰亚胺、聚酰亚胺苯并噁唑、聚苯并噁唑、环状烯烃聚合物、金属皂、卵磷脂、蜡、尼龙、乳胶和有机硅橡胶、以及它们的混合物。
在一些实施方案中,有机硅交联聚合物诸如XPL,如Nature Materials(DOI:10.1038/NMAT 4635,15,911-918,2016)中所述。
颜料材料
着色区域30和着色层(130、230和330)包含用于在掩饰化妆贴片施用区域中匹配使用者皮肤颜色的颜料。着色区域/层通过将着色剂混合到相对中性或无色材料的基质中而形成。
制造中使用的大多数颜料为被研磨成细粉并添加到基质材料的干燥着色剂。着色剂可为颜料和染料,这取决于使用其所处的基质材料。
认证的颜色可为有机化合物或无机金属盐。可用的无机颜料的示例包括金属氧化物,诸如铁氧化物(黄、红、棕或黑)、二氧化钛(白)、氧化锌、氧化铬(绿),以及其他材料,包括氰亚铁酸铵铁(蓝)、锰紫、群青(包含少量聚硫化物的沸石基矿物)蓝、滑石、卵磷脂改性滑石、沸石、高岭土、卵磷脂改性高岭土、锆、胭脂红(胭脂红酸的铝盐)、云母、碳酸镁、镉-钡红深、黄赭石、煅黄土、以及它们的混合物。还可用的是涂有透明金属氧化物的二氧化硅珠。
铁氧化物(也称为美容胶粒)具有各种颜色,这些颜色分为三种主要颜色:黄色铁氧化物(氧化铁水合物,或FeO(OH))、红铁丹(氧化铁,Fe2O3)、以及黑色铁氧化物(四氧化三铁,或Fe3O4(Fe2O3/FeO))。通过以不同比率混合这三组铁氧化物来产生各种皮肤颜色。
可用的无机颜料的示例包括天然着色剂以及合成单体和聚合物着色剂。示例性为酞菁蓝和绿颜料、联苯胺黄和橙颜料、以及偶氮型红和黄颜料诸如甲苯胺红、立索红、萘酚红和棕颜料。还可用的是色淀,其为通过将有机染料沉淀和吸收在不溶性基底诸如氧化铝、钡或钙水合物上而形成的颜料。尤其优选的色淀主要为FD&C或D&C色淀以及它们的共混物。还可采用染剂,诸如溴染料和荧光素染料。
光学改性剂
光学改性区域40和光学改性层(140、240、340、350和360)改性以下特性中的一个或多个:光的透射、反射和吸收。光学改性区域/层通过将光学改性剂混合到相对中性或无色材料的基质中而形成。
光学改性剂包括如下材料:吸收光、反射光、散射光、遮光剂和干涉颜料。
光吸收材料包括:对氨基苯甲酸、对氨基苯甲酸酯、西诺沙酯、anthralinate、肉桂酸酯、胡莫柳酯、苯酮、咖啡粉、以及这些的混合物。
光反射材料包括:二氧化钛、滑石、氧化锌、以及这些的混合物。
光散射材料包括粉末诸如:硼硅酸钙铝(LuxsilTM)、PMMA(微球M-100)、聚乙烯(聚氯乙烯2080)、甲基丙烯酸甲酯交叉聚合物(Covabeads 2002)、尼龙-12(Orgasol 2002ONatCos C)、氧化铝(Al2O3)、乙烯/丙烯酸共聚物(Flobeads EA209)、以及两种或更多种粉末的混合物。这些粉末在使用时以按总组合物的重量计约0.001%至约20%,优选地约1%至约10%的量存在。
遮光剂包括:中性格鲁吉亚高岭土粉末、煅烧的高岭土粉末、Artskin white、干燥颜料钛(Ti)白、或Ti白艺术油色、以及这些的混合物。
干涉颜料包括:以TiO2、Fe2O3或Cr2O3的50—300nm膜层化的云母。此类颜料通常为珠光的,并且可为未涂覆的或经涂覆的。涂料包括但不限于二氧化硅、尼龙或聚甲基丙烯酸甲酯(PMMA)。可用的干涉颜料可商购自许多供应商,例如Rona(TimironTM和DichronaTM)、Presperse(FlonacTM)、Englehard(DuochromeTM)、以及Kobo(SK-45-R和SK-45-G)。尤其可用的产品的示例为涂有TiO2薄层并且还涂有PMMA珠(Kobo-LSBPA050/MicaR)的云母,其产生有吸引力的红色颜色而无不期望的珠光度;以及Flamenco Red(Engelhard),一种涂有TiO2的云母。干涉颗粒的可用尺寸范围为约1至约200p,并且优选地为约3至约100g。干涉颜料以约0.05重量%至90重量%的量使用,该范围的高端最适合用于压粉产品中。然而,在大多数类型的产品中,干涉颜料的量将在约0.5%至约15%的范围内,该范围的下端用于未着色的(即,不具有非干涉颜料)或轻度着色的产品,并且该范围的较高端用于更深着色的产品中。
在一些实施方案中,构成本发明贴片10、100、200和300的柔性膜20、120、220和320包含至少一种活性物质、活性剂或有益剂。可用于本发明的膜结构中的有益剂包括美容剂和治疗剂。此类物质可为包括而不限于以下多种组合物中的任一种:透明质酸;羟基酸(例如,羟基乙酸、乳酸、苹果酸、水杨酸、柠檬酸、酒石酸);抗痤疮剂(例如,水杨酸、视黄醇、类视色素或其它角质层分离剂以及过氧化苯甲酰或用于治疗痤疮的其它抗微生物剂);光泽控制剂(例如,大米蛋白、棉粉、新康唑(elubiol)(二氯苯基-二氧戊环咪唑(imidazoltioxolan));类视色素或它的衍生物,诸如维甲酸、异维甲酸、莫维A胺、阿达帕林、他佐罗汀、壬二酸和视黄醇;氨基酸的5-α-还原酶抑制剂,例如甘氨酸衍生物;水解植物蛋白,包括大豆蛋白和小麦蛋白等;绿茶(camellia sinesis)提取物和肉桂树皮提取物);保湿剂;抗微生物剂(例如苯扎氯铵、苄索氯铵、三氯卡班、聚六亚甲基双胍、十六烷基氯化吡啶鎓、甲苄索氯铵;氯己定的盐,转染碘代丙炔基氨基甲酸丁酯、双咪唑烷基脲、双葡萄糖酸氯己定、醋酸氯己定、羟乙基磺酸氯已定和盐酸氯已定;卤代酚类化合物,诸如2,4,4',-三氯-2-羟基二苯醚(三氯生);对氯间二甲苯酚(PCMX);短链醇诸如乙醇、丙醇等);抗生素或防腐剂(莫匹罗星、硫酸新霉素杆菌肽、多粘菌素B、1-氧氟沙星、四环素类(盐酸氯四环素、10盐酸氧四环素和盐酸四环素)、磷酸克林霉素、硫酸庆大霉素、甲硝唑、己基间苯二酚、甲基苄索氯铵、苯酚、季铵化合物、茶树油及它们药学上可接受的盐和前药)、抗炎剂(例如合适的甾体抗炎剂,诸如皮质类固醇,诸如氢化可的松,羟基去炎松、α甲基地塞米松、磷酸地塞米松、二丙酸倍氯米松、戊酸氯倍他索、地奈德、去羟米松、醋酸去氧皮质酮、地塞米松、二氯松、二醋酸二氟松、戊酸二氟可龙、氟德诺龙(fluadrenolone)、氟氯缩松丙酮化物(fluclarolone acetonide)、氟氢可的松、新戊酸氟米松、醋酸氟轻松(fluosinol oneacetonide)、氟轻松、氟可丁酯(flucortine butylester)、氟可龙、醋酸氟泼尼定(氟强的松)、氟氢缩松、哈西奈德、醋酸氢化可的松、丁酸氢化可的松、甲基泼尼松龙、醋酸曲安奈德、可的松、可托多松、醋酸氟轻松(flucetonide)、氟氢可的松、二醋酸二氟拉松(difluorosone diacetate)、fluradrenalone acetonide、甲羟松、安西法尔(amciafel)、安西非特、倍他米松、氯泼尼松(chlorprednisone)、醋酸氯泼尼松、氯可托龙(clocortelone)、克辛诺龙(clescinolone)、二氯松、二氟泼尼酯、氟氯奈德、氟尼缩松、氟米龙、氟培龙、氟泼尼龙、戊酸氢化可的松、环戊基丙酸氢化可的松、氢可他酯、甲泼尼松、帕拉米松、泼尼松龙、强的松、二丙酸倍氯米松、二丙酸倍他米松、去炎松和盐、非甾体类抗炎剂、小白菊(Tanacetum parthenium)、枸杞(Lycium barbarum)、奶蓟提取物(Silybummarianum)、苋菜油(Amaranthus cruentus)、石榴(Punica granatum)、巴拉圭茶提取物(Ilex paraguariensis叶提取物),白色百合花提取物(Lilium Candidum)、橄榄叶提取物(Olea europaea)和根皮素(苹果提取物));抗霉菌/抗真菌剂(例如,咪康唑、益康唑、酮康唑、舍他康唑、伊曲康唑、氟康唑、伏立康唑、氯碘羟喹、比佛那唑(bifoconazole)、特康唑、布康唑、噻康唑、奥苷康唑、硫康唑、沙康唑、克霉唑、十一烯酸、卤普罗近、布替萘芬、托萘酯、制霉菌素、环吡酮胺、特比萘芬、阿莫罗芬、萘替芬、新康唑、灰黄霉素、以及它们的药学上可接受的盐和前药;唑、烯丙胺或它们的混合物);外用止痛剂(例如布洛芬或双氯芬酸);辣椒素,芬太尼及其盐,诸如枸橼酸芬太尼;对乙酰氨基酚(如扑热息痛);非类固醇类抗炎剂(NSAID)诸如水杨酸盐;阿片类药物诸如吗啡和羟考酮;含布洛芬或双氯芬酸的凝胶);抗氧化剂(例如,巯基化合物及其衍生物(例如,焦亚硫酸钠和N-乙酰半胱氨酸)、硫辛酸和二氢硫辛酸、白藜芦醇、乳铁蛋白;抗坏血酸、抗坏血酸酯和抗坏血酸衍生物(例如,抗坏血酸棕榈酸酯和抗坏血酸多肽);丁基羟基苯甲醚、丁基化羟基甲苯(丁基羟基甲苯)、类视色素(例如视黄醇和棕榈酸视黄酯)、生育酚(例如乙酸生育醇酯)、生育三烯酚和泛醌;半胱氨酸、N-乙酰半胱氨酸、亚硫酸氢钠、偏亚硫酸氢钠、甲硫酸氢钠、丙酮亚硫酸氢钠、生育酚和去甲二氢愈创木酸;包含类黄酮和异黄酮及它们的衍生物的提取物(例如,染料木黄酮和黄豆苷元);含白藜芦醇等的提取物;葡萄籽、绿茶、松树皮和蜂胶;植物来源的多酚抗氧化剂诸如丁香、肉桂、牛至、姜黄、小茴香、欧芹、罗勒属植物、咖喱粉、芥菜籽、姜、辣椒、辣椒粉、甜辣椒、大蒜、芫荽、洋葱和小豆蔻;典型的香草诸如鼠尾草、百里香、牛至属植物、龙蒿、胡椒薄荷、牛至、香薄荷、罗勒属植物和莳萝叶));脱毛剂(例如,巯基乙醇酸钙或巯基醇酸钾);维生素(例如,维生素A、维生素B、维生素C、维生素E;α、β、γ或δ生育酚,烟酸或烟酰胺)和维生素盐或衍生物,诸如抗坏血酸二葡萄糖酸盐和乙酸维生素E或棕榈酸酯;防晒霜(例如二氧化钛)和/或防晒剂(例如无机防晒剂,诸如二氧化钛和氧化锌;有机防晒剂,诸如甲氧基肉桂酸辛酯、水杨酸辛酯、胡莫柳酯、阿伏苯宗);血管扩张剂(例如,烟酸):湿润剂(例如,甘油);抗衰老剂(例如,类视色素;二甲基氨乙醇(DMAE),含铜的肽);α-羟基酸或果酸及其前体诸如乙醇酸、柠檬酸、乳酸、苹果酸、扁桃酸、抗坏血酸、α-羟基丁酸、α-羟基异丁酸、α-羟基异己酸、阿卓乳酸、α-羟基异戊酸、丙酮酸乙酯、半乳糖醛酸、葡庚糖酸、葡萄七酮并1,4-内酯、葡糖酸、葡糖酸内酯、葡糖醛酸、葡糖醛酸内酯、丙酮酸异丙酯、丙酮酸甲酯、粘酸、丙酮酸、葡糖二酸、糖质酸1,4-内酯、酒石酸和丙醇二酸;β-羟基酸诸如β-羟基丁酸、β-苯基-乳酸和β-苯基丙酮酸;锌和含锌的化合物诸如氧化锌;植物提取物诸如绿茶、大豆、乳蓟、藻类、芦荟、当归、苦橙、咖啡、黄连、柚子、茯苓(hoellen)、忍冬、薏苡、紫草、桑树、芍药、葛根、大米、燕麦(呈胶态和/或油形式)、香菇、海藻、黑莓、南方木材、莲花、小麦和红花、以及它们的盐和前药);类胡萝卜素、神经酰胺、脂肪酸、酶、酶抑制剂、矿物质、类固醇、肽、氨基酸、植物提取物、着色剂等。这些物质可以多种方式影响皮肤,诸如通过保湿;增强肤色或着色(诸如用颜料);治疗或至少减轻各种皮肤状况(诸如皮肤干燥或严重干燥、湿疹、牛皮癣、特应性皮炎、过敏性皮疹、痤疮、黑头、脓疱、黑头粉刺、酒渣鼻、带状疱疹、皱纹、唇疱疹、疱疹、鸡眼、疣、晒斑、昆虫叮咬、毒藤疹等);施加机械力(诸如收缩)以平滑皱纹;或更一般地,治疗或减轻不期望的皮肤缺陷(诸如眼暗圆、发红痤疮、细纹和皱纹、炎症后色素沉着过度(PIH)、发红、炎症、脂肪团、皱纹、老年斑、斑状色素沉着、色斑、黄褐斑、眼下浮肿)的症状和外观;移除不想要的面部或身体毛发;帮助创伤愈合;等。例如,可将洗剂、霜膏、油甚至面膜施用到皮肤上来治疗或以其它方式影响皮肤。此类个人或消费者保健物质一般遵循扩散原理吸收到皮肤中,在该扩散原理下,穿过皮肤的扩散或输送速率与皮肤两侧上的活性物质浓度差相关。
在一些实施方案中,本发明的掩饰化妆贴片为个性化的消费者颜色匹配贴片,其掩饰不想要的瑕疵和皮肤状况,同时递送制剂和活性剂。该贴片通过利用诊断和成像技术分析消费者的待处理和掩饰皮肤区域从而得到完全个性化的皮肤溶液来提供对不想要的皮肤状况和瑕疵的优越掩饰。优点包括:优越的瑕疵遮藏和掩饰、与标准化妆品相比快速且无皮肤刺激的瑕疵遮藏方法、以及与化妆品相比更长的持久性能和耐久性。
在一些实施方案中,将智能电话或等同图像捕获设备与计算机视觉和机器学习结合使用以收集个性化皮肤信息(形状/几何形态、微观几何形态和光泽度、颜色、半透明度)。利用计算机模拟程序诸如CONTONING,经由MULTI-MATERIALS和CONTONING技术来模拟高水平准确性和天然患者皮肤特性诸如形状、微观几何形态、纹理、光泽度、颜色、半透明度。结果为向患者“上漆”(将有问题皮肤的外观改变为期望的状态)推荐以解决不想要的皮肤状况。
在一些实施方案中,使用人工智能和诊断,经由监督机器学习w/专业带注释的皮肤图像并结合使用者偏好反馈来生成治疗推荐。然后,计算机模型使用CNN(卷积神经网络)推荐精确的治疗预测。
本发明的掩饰化妆贴片可使用增材制造技术生产。增材制造是一组用于使用三维计算机辅助设计(CAD)数据快速制造物理部件或组件的技术。部件或组件的构造通常使用“增材层制造”技术诸如3D打印来完成。增材制造是制造具有多个层和表面特征的掩饰化妆贴片的简单、有效且经济的方法。
一般来讲,计算机辅助设计-计算机辅助制造CAD-CAM工作流是传统的增材制造工艺。该工艺从创建几何数据开始,该几何数据可以是使用CAD工作站的3D实体,也可以是使用扫描装置的2D切片。对于增材制造,此数据必须代表有效的几何模型;即,其边界表面包围有限体积的几何模型不包含暴露内部的孔,除非它们被设计到结构中,并且不会折叠回自身。换句话讲,对象必须具有“内部”。如果对于3D空间中的每个点,算法可以唯一地确定该点是位于模型的边界表面内部、之上还是外部,则该模型是有效的。CAD后处理程序将使用简化的数学形式来近似内部CAD几何形式,而该数学形式又以指定的数据格式表示,这是增材制造中的一个常见特征。为了获得驱动增材制造机构的必要运动控制轨迹,通常将所制备的几何模型切成各层,并且将各切片扫描成行(从而如在计算机数字控制工具路径中产生用于生成轨迹的“2D绘图”),从而致使层到层物理构建过程。
3D打印工艺能够产生不同尺寸和形状的掩饰化妆贴片,以及产生具有不止一种材料的多层贴片阵列的能力。可将软质材料、硬质材料以及甚至液体结合到单独的层或区域中。也可将不相容的化合物构建到掩饰化妆贴片的不同区段中,而没有交叉污染的担忧。
本发明的贴片10、100、200和300可用作在期望的人类皮肤区域中掩饰瑕疵的方法。该方法包括以下步骤:(a)将与所述期望的人类皮肤区域相关的图像数据提供给计算机,其中所述计算机将所述图像数据转换成几何数据,所述几何数据代表所述期望的人类皮肤区域的几何模型;(b)使用所述几何数据来控制3D打印机以打印用于向所述期望区域施用的贴片,以及将所述贴片施用到所述期望的皮肤区域。
在一些实施方案中,几何数据可用于确定人类皮肤的需要有益剂的子区域。在这些实施方案中,3D打印机在贴片的子区域中打印有益剂,该贴片的子区域对应于人类皮肤的需要有益剂的子区域。
实施例
实施例1:单层掩饰化妆贴片。
参考图1至图3,单层掩饰贴片包括:在贴片的一个外表面上的薄丙烯酸类粘合剂沉积物诸如BASF丙烯酸类粘合剂,在该贴片中粘合剂沉积物可覆盖整个表面或被策略地放置在第一面向外的主表面22上;以及在第二面向外的主表面24上的半透明天然皮肤匹配颜色和纹理成品。整个单层掩饰化妆贴片10是使用医疗级有机硅弹性体诸如Silastic MDX4-4210(其得自Dow Corning Corporation(Midland,MI))在Stratasys OBJ260 Connex3打印机(Stratasys Ltd.,Eden Prairie,MN)或等同物上3D打印的,其具有预混着色剂诸如红铁丹(氧化铁Fe2O3,其得自Clarke Colors LLC,Marietta,GA)以及遮光剂诸如TiO2(二氧化钛(Sigma–Aldrich,#224227,平均尺寸为1μm并且最大尺寸为5μm)),以模拟天然皮肤的颜色、透明度、反射率、纹理和不透明度。一种匹配人类皮肤的方法可通过将合适浓度的TiO2颗粒和美容粉末/颜料诸如红铁丹(氧化铁Fe2O3)与有机硅橡胶混合来实现;这在400至1,000nm的波长范围内产生人类皮肤的光学特性。用于3D打印贴片的医疗级有机硅的硬度/硬性和弹性还需要匹配人类皮肤,人类皮肤硬性的典型值为50-55肖氏硬度A,其具有大约7,000-12,000psi的挠曲模量,这取决于使用者的皮肤特征和特性。颜料和遮光剂预混在增材制造(AM)喷射材料中,或者在3D打印工艺期间在沉积点处混合。参考图3中光学改性区域40a至40f,可在3D打印工艺期间在策略位置处添加增添物,以减轻待靶向的期望皮肤状况。将活性物质诸如治疗痤疮的水杨酸和视黄醇沉积在粘合剂沉积物之间以确保针对每个增添物的直接皮肤接触。活性物质的载体具有允许其模拟天然皮肤颜色、透明度、反射率、纹理和不透明度从而为待处理的皮肤状况提供掩饰的物理特性。
实施例2:多层掩饰化妆贴片。
参考图6,多层掩饰化妆贴片200的三层实施方案实施例包括第一薄丙烯酸类(例如BASF丙烯酸粘合剂)粘合剂层250,在该贴片中粘合剂沉积物可产生整个层或被策略地放置以允许活性物质沉积在开放区域中,从而允许活性物质能够接触皮肤并处理特定的皮肤状况。在该三层掩饰化妆贴片200构造中,光学改性层240是使用医疗级有机硅弹性体诸如MDX4-4210(其得自Dow Corning Corporation(Midland,MI))构造的,其具有预混遮光剂诸如TiO2(二氧化钛(Sigma–Aldrich,#224227,平均尺寸为1μm并且最大尺寸为5μm)),以模拟天然皮肤的透明度、反射率和不透明度。光学改性层240也可通过在粘合剂层250的初始粘合剂/活性物质之上选择性地3D打印期望的活性物质而被构造成包含活性物质以减轻某些皮肤状况。一旦粘合剂层250的活性物质溶解到皮肤中,粘合剂层250的溶解活性物质后面的3D打印活性物质便暴露于皮肤表面并且可作用于待处理的皮肤状况。着色层230也由医疗级有机硅弹性体诸如Silastic MDX4-4210(其得自Dow CorningCorporation(Midland,MI))构成,其具有预混着色剂诸如红铁丹(氧化铁Fe2O3,其得自Clarke Colors LLC,Marietta,GA,平均尺寸为1μm并且最大尺寸为5μm),以模拟天然皮肤的皮肤颜色、透明度、反射率、纹理和不透明度。整个多层掩饰化妆贴片200是在StratasysOBJ260 Connex3打印机(Stratasys Ltd.,Eden Prairie,MN)或等同物上3D打印的。用于3D打印贴片的医疗级有机硅的硬度/硬性和弹性还需要匹配人类皮肤,人类皮肤硬性的典型值为50-55肖氏硬度A,其具有大约7,000-12,000psi的挠曲模量,这取决于使用者的皮肤特征和特性。颜料和遮光剂预混在增材制造(AM)喷射材料中,或者在3D打印工艺期间在沉积点处混合。可在3D打印工艺期间在策略位置处添加增添物,以在着色层230或光学改性层240中减轻待靶向的期望皮肤状况。将活性物质诸如治疗痤疮的水杨酸和视黄醇沉积在粘合剂沉积物之间以确保针对每个增添物的直接皮肤接触。活性物质的载体具有允许其模拟天然皮肤颜色、透明度、反射率、纹理和不透明度从而为待处理的皮肤状况提供掩饰的物理特性。
提供以上说明书、实施方案和实施例以帮助本文公开的发明的完整性和非限制性理解。由于在不脱离本发明的实质和范围的情况下,可以做出本发明的许多变型和实施方案,因此本发明由以下所附的权利要求书限定。
Claims (23)
1.一种用于向人类皮肤施用的贴片,所述贴片包含柔性膜,所述柔性膜具有
(a)第一面向外的粘合剂主表面;
(b)第二面向外的表面,所述第二面向外的表面经纹理化以对应于使用期间被所述贴片覆盖的皮肤;
(c)至少一个着色层;以及
(d)至少一个适于改性一个或多个光学特性的层,所述一个或多个光学特性选自光透射、光反射和光吸收。
2.根据权利要求1所述的贴片,其中所述第一表面包含压敏粘合剂层。
3.根据权利要求1所述的贴片,其中所述柔性膜被布置和构造成覆盖皮肤瑕疵,并且其中所述至少一个着色层和所述至少一个适于改性一个或多个光学特性的层被布置和构造成对应于无瑕疵皮肤。
4.根据权利要求1所述的贴片,其中所述至少一个适于改性一个或多个光学特性的层适于改性至少两个光学特性,所述至少两个光学特性选自光透射、光反射和光吸收。
5.根据权利要求1所述的贴片,所述贴片还包含至少一种有益剂。
6.根据权利要求5所述的贴片,其中所述至少一种有益剂包括抗生素。
7.根据权利要求1所述的贴片,其中所述着色层是连续地着色的。
8.根据权利要求1所述的贴片,其中所述着色层具有由非着色区域隔开的离散着色区域。
9.根据权利要求1所述的贴片,其中所述着色层具有至少一个第一着色区域和至少一个第二着色区域,其中所述第一着色区域和所述第二着色区域是不同地着色的。
10.一种用于向人类皮肤施用的贴片,所述贴片包含柔性膜,所述柔性膜具有第一面向外的粘合剂层、与所述第一面向外的粘合剂层相对的第二面向外的主表面,所述第二面向外的主表面经纹理化以对应于使用期间被所述贴片覆盖的皮肤;其中所述柔性膜还包括设置在所述第一面向外的粘合剂层和所述第二面向外的主表面之间的至少一个着色层和至少一个适于改性一个或多个光学特性的层,所述一个或多个光学特性选自光透射、光反射和光吸收。
11.根据权利要求10所述的贴片,其中所述柔性膜被布置和构造成覆盖皮肤瑕疵,并且其中所述至少一个着色层和所述至少一个适于改性一个或多个光学特性的层被布置和构造成对应于无瑕疵皮肤。
12.根据权利要求10所述的贴片,其中所述至少一个适于改性一个或多个光学特性的层适于改性至少两个光学特性,所述至少两个光学特性选自光透射、光反射和光吸收。
13.根据权利要求10所述的贴片,所述贴片还包含至少一种有益剂。
14.根据权利要求13所述的贴片,其中所述至少一种有益剂包括抗生素。
15.根据权利要求10所述的贴片,其中所述粘合剂层包括连续的压敏粘合剂层。
16.根据权利要求10所述的贴片,其中所述粘合剂层包括离散的压敏粘合剂区域。
17.一种贴片,所述贴片包含多个层,具有粘合剂的第一外层,第一外表面,第二外表面,与粘合剂层相关联的第一层;具有与其相关联的至少一个形成纹理化表面的层的第二外层,以及至少一个设置在所述第一粘合剂层和所述第二外表面之间的中间层,所述至少一个中间层具有至少一个着色区域或层以及至少一个适于改性一个或多个光学特性的区域或层,所述一个或多个光学特性选自光透射、光反射和光吸收。
18.根据权利要求17所述的贴片,其中所述柔性膜被布置和构造成覆盖皮肤瑕疵,并且其中所述至少一个着色区域或层以及所述至少一个适于改性一个或多个光学特性的区域或层被布置和构造成对应于无瑕疵皮肤。
19.根据权利要求17所述的贴片,其中所述至少一个适于改性一个或多个光学特性的区域或层适于改性至少两个光学特性,所述至少两个光学特性选自光透射、光反射和光吸收。
20.根据权利要求17所述的贴片,所述贴片还包含至少一种有益剂。
21.根据权利要求20所述的贴片,其中所述至少一种有益剂包括抗生素。
22.根据权利要求17所述的贴片,其中所述粘合剂层包括连续的压敏粘合剂层。
23.根据权利要求17所述的贴片,其中所述粘合剂层包括离散的压敏粘合剂区域。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762525425P | 2017-06-27 | 2017-06-27 | |
US62/525,425 | 2017-06-27 | ||
CN201880043115.5A CN110799156B (zh) | 2017-06-27 | 2018-06-27 | 具有治疗特性的多功能个性化贴片 |
PCT/IB2018/054771 WO2019003152A1 (en) | 2017-06-27 | 2018-06-27 | CUSTOM MULTIFUNCTIONAL STAMP WITH THERAPEUTIC PROPERTIES |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880043115.5A Division CN110799156B (zh) | 2017-06-27 | 2018-06-27 | 具有治疗特性的多功能个性化贴片 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114848506A true CN114848506A (zh) | 2022-08-05 |
Family
ID=63207794
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210561820.2A Pending CN114848506A (zh) | 2017-06-27 | 2018-06-27 | 具有治疗特性的多功能个性化贴片 |
CN201880043115.5A Active CN110799156B (zh) | 2017-06-27 | 2018-06-27 | 具有治疗特性的多功能个性化贴片 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880043115.5A Active CN110799156B (zh) | 2017-06-27 | 2018-06-27 | 具有治疗特性的多功能个性化贴片 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11717448B2 (zh) |
EP (1) | EP3644917A1 (zh) |
KR (1) | KR20200024856A (zh) |
CN (2) | CN114848506A (zh) |
AU (1) | AU2018291078B2 (zh) |
BR (1) | BR112019027846A8 (zh) |
RU (1) | RU2763393C2 (zh) |
WO (1) | WO2019003152A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117942427A (zh) * | 2024-03-27 | 2024-04-30 | 吉林农业科技学院 | 一种可注射智能控释水凝胶及其在治疗骨骼损伤中的应用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110664541A (zh) * | 2019-09-25 | 2020-01-10 | 北京科技大学 | 一种3d打印的伤口定制化的创可贴的制备方法 |
CN116322852A (zh) * | 2020-10-05 | 2023-06-23 | 皇家飞利浦有限公司 | 创建定制颜色的粘合固定装置的系统和方法 |
US20230131013A1 (en) * | 2021-10-26 | 2023-04-27 | Ashley Merrill | Weighted, Cooling Sleep Mask |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5368553A (en) * | 1991-07-12 | 1994-11-29 | Newman; Nancy M. | Invisible bandage assembly |
US20150157509A1 (en) * | 2013-12-11 | 2015-06-11 | Oscar Polk Atkinson | Occlusive skin covering |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5320835A (en) | 1989-10-25 | 1994-06-14 | Avon Products, Inc. | Cosmetic formulation having a palette of color shades renewable by mechanical action |
CA2066411A1 (en) | 1989-11-17 | 1991-05-18 | Dennis L. Krueger | Elastomeric laminates with microtextured skin layers |
US6394613B1 (en) | 1997-08-07 | 2002-05-28 | Canon Kabushiki Kaisha | Anti-fogging and anti-reflection optical article |
US6117435A (en) | 1998-06-24 | 2000-09-12 | Color Access, Inc. | Natural look cosmetic compositions |
DE10335231B4 (de) | 2003-08-01 | 2007-06-28 | Lts Lohmann Therapie-Systeme Ag | Verfahren zur Verbesserung der Durchlässigkeit der menschlichen Haut und Pflaster für die transdermale Zufuhr von Wirkstoffen |
EP1660157A4 (en) | 2003-08-07 | 2009-04-15 | James Price | COSMETIC BANDAGE |
US7517571B2 (en) * | 2004-05-12 | 2009-04-14 | Barbara Funke | Temporary tattoo for neutralizing or blocking skin imperfections |
US20120029405A1 (en) | 2010-07-31 | 2012-02-02 | Anthony Cataldi | Scented And Antiseptic Adhesive Bandage |
WO2014149719A1 (en) * | 2013-03-15 | 2014-09-25 | Avon Products, Inc | Multi-layer cosmetic films |
US10330832B2 (en) * | 2015-06-25 | 2019-06-25 | Apple Inc. | High-luminance surface |
EP3291781A4 (en) * | 2016-06-02 | 2018-10-31 | Jones, Geana | Skin cover and medical device |
-
2018
- 2018-06-27 CN CN202210561820.2A patent/CN114848506A/zh active Pending
- 2018-06-27 US US16/625,155 patent/US11717448B2/en active Active
- 2018-06-27 AU AU2018291078A patent/AU2018291078B2/en active Active
- 2018-06-27 EP EP18755303.7A patent/EP3644917A1/en active Pending
- 2018-06-27 CN CN201880043115.5A patent/CN110799156B/zh active Active
- 2018-06-27 WO PCT/IB2018/054771 patent/WO2019003152A1/en unknown
- 2018-06-27 BR BR112019027846A patent/BR112019027846A8/pt unknown
- 2018-06-27 KR KR1020207002454A patent/KR20200024856A/ko not_active Application Discontinuation
- 2018-06-27 RU RU2020102872A patent/RU2763393C2/ru active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5368553A (en) * | 1991-07-12 | 1994-11-29 | Newman; Nancy M. | Invisible bandage assembly |
US20150157509A1 (en) * | 2013-12-11 | 2015-06-11 | Oscar Polk Atkinson | Occlusive skin covering |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117942427A (zh) * | 2024-03-27 | 2024-04-30 | 吉林农业科技学院 | 一种可注射智能控释水凝胶及其在治疗骨骼损伤中的应用 |
CN117942427B (zh) * | 2024-03-27 | 2024-05-28 | 吉林农业科技学院 | 一种可注射智能控释水凝胶及其在治疗骨骼损伤中的应用 |
Also Published As
Publication number | Publication date |
---|---|
US11717448B2 (en) | 2023-08-08 |
AU2018291078A1 (en) | 2020-01-16 |
CN110799156B (zh) | 2022-05-24 |
RU2763393C2 (ru) | 2021-12-28 |
EP3644917A1 (en) | 2020-05-06 |
CN110799156A (zh) | 2020-02-14 |
KR20200024856A (ko) | 2020-03-09 |
BR112019027846A2 (pt) | 2020-07-07 |
RU2020102872A (ru) | 2021-07-27 |
WO2019003152A1 (en) | 2019-01-03 |
AU2018291078B2 (en) | 2024-02-22 |
RU2020102872A3 (zh) | 2021-08-03 |
US20210059860A1 (en) | 2021-03-04 |
BR112019027846A8 (pt) | 2022-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110799156B (zh) | 具有治疗特性的多功能个性化贴片 | |
US20210093072A1 (en) | System for targeted application of topical agents to an isolated body part | |
US20230046265A1 (en) | Absorbent articles comprising graphics | |
CN104244910A (zh) | 抚平皱纹和皮肤肌理缺陷的方法 | |
US10682292B2 (en) | Applied films for smoothing wrinkles and skin texture imperfections | |
US20150016862A1 (en) | Applicator for applying compositions that smooth wrinkles and skin texture imperfections | |
CN106029173A (zh) | 对角蛋白材料进行化妆的转移装置和方法 | |
CA2805202C (en) | Absorbent articles comprising graphics | |
CN111671658A (zh) | 遮瑕贴及其制造方法、肌肤美白护肤方法和抗痘护肤方法 | |
JP6103736B2 (ja) | 塗布器 | |
JP7390656B2 (ja) | インク、貼付用キット、貼付用シート、及び貼付用シートを製造する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240328 Address after: new jersey Applicant after: JOHNSON & JOHNSON CONSUMER COMPANIES, Inc. Country or region after: U.S.A. Address before: new jersey Applicant before: JOHNSON & JOHNSON CONSUMER COMPANIES, Inc. Country or region before: U.S.A. |
|
TA01 | Transfer of patent application right |